A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects

Phase 1 Completed 168 enrolled Novo Nordisk A/S

RandomizedParallel-groupDouble-blindTreatment

This trial is conducted in Europe. The aim of the trial is to evaluate the effect of semaglutide on cardiac repolarisation in healthy subjects.

Evaluation	Drug	Modality	Dose	Route
Subject	Moxifloxacin	Small molecule	400 mg	Oral
Subject	Semaglutide	Peptide	1.5 mg	Subcutaneous